CUMYL-CH-MEGACLONE
A synthetic cannabinoid with a γ-carbolin-1-one nucleus, a high-efficacy CB1 agonist, scheduled as a narcotic in France.
C₂₇H₃₀N₂O
Harm-reduction warning
No characterised human dose: animal / in vitro data only. Effect profile, safety margin and acute toxicity are not documented in human clinical practice. Extremely potent compound: severe effects, seizures and deaths reported in the literature.
Data sheet
Names
- IUPAC name
- 5-(cyclohexylmethyl)-2-(2-phenylpropan-2-yl)pyrido[4,3-b]indol-1-one
- Other names
- SGT-270 · SGT270 · Cumyl-cyclohexyl-pegaclone
Identifiers
- Formula
- C₂₇H₃₀N₂O
- Molar mass
- 398.50 g/mol
- PubChem CID
- 155884822(new tab)
- InChIKey
- CGHCGYCTOLWAPL-UHFFFAOYSA-N
Class
- Family
- Synthetic cannabinoid (SCRA)
Updated on
Receptors and activity
- CB1Agonist95 out of 100
Ki 1,01 nM (Haschimi et coll., 2021) ; EC50 1,22 nM, Emax 143,4 % au-dessus de l'activité constitutive (hCB1)
Subjective signature
- Calm
- 12 out of 100
- Relaxation of body and mind; reduced mental noise without marked drowsiness.
- Clarity
- 5 out of 100
- Sustained attention and clear thinking; functional lucidity, not euphoria.
- High
- 18 out of 100
- Euphoria and sensory intensity; altered perception of time and space.
- Appetite
- 20 out of 100
- Stimulation of hunger and of taste appreciation (the “munchies” effect).
- Sleep
- 12 out of 100
- Sedative effect: aids sleep onset and the continuity of deep sleep.
Pharmacology
CUMYL-CH-MEGACLONE is a synthetic agonist of the cannabinoid receptors, of the γ-carbolin-1-one family, and the cyclohexylmethyl analogue of CUMYL-PEGACLONE. Haschimi et al. (2021) measure at hCB1 a Ki of 1.01 nM, an affinity about 2.5 times higher than that of JWH-018, and an EC50 of 1.22 nM, with high efficacy (Emax of 143.4% above the receptor's constitutive activity). The authors suggest that it more closely resembles CUMYL-PEGACLONE pharmacologically. First identified in Hungary in December 2018 in a herbal blend, it was later found in samples from intoxicated patients. The file remains thin: no clinical study and no assessment of abuse potential in humans was found in the sources consulted, pharmacokinetics is documented only through a few blood samples, and the molecule is not listed in the INCB 2026 Green List, although it is scheduled as a narcotic in France.
Key sources.
- Haschimi et coll., Cumyl-CH-MEGACLONE : métabolisme de phase I humain et caractérisation pharmacologique, J Anal Toxicol, 2021 (new tab)PMID 32514544
- Institóris et coll., Symptômes cliniques et concentrations sanguines de NPS chez des patients intoxiqués, région de Budapest (2018-2019), Clin Toxicol, 2022 (new tab)PMID 34080493
- ANSM, Décision du 22 mai 2024 portant modification de la liste des substances classées comme stupéfiants (new tab)
- ANSM, Liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026 (annexe IV) (new tab)
- OICS, Liste verte des substances psychotropes sous contrôle international, édition 2026 (new tab)
- PubChem, CUMYL-CH-MEGACLONE, CID 155884822 (new tab)
History
- Source
- Fully synthetic molecule, with no known plant origin. It was identified in a herbal blend in which it was the main active ingredient. Its γ-carbolinone nucleus places it in the same chemical family as CUMYL-PEGACLONE (Haschimi et al., 2021).
Origin (pharmaceutical research → illicit market)
No known biosynthetic pathway: a synthetic molecule of the γ-carbolin-1-one class, with no known link to hemp or other plants.
Legal framework
- European Union
No harmonised European Union control measure has been found for this molecule in the sources consulted, and it does not appear in the INCB 2026 Green List, which reproduces the schedules of the 1971 Convention.
- France
In France, this substance is scheduled as a narcotic by name. The ANSM decision of 22 May 2024, published on 24 May 2024, added “CUMYL-CH-MEGACLONE ou SGT-270” to annex IV of the decree of 22 February 1990, under the heading “Les cannabinoïdes suivants”. It is therefore not a mere attachment to a generic clause: the name appears on the consolidated list published by ANSM. Possession, transfer and use fall under the criminal regime for narcotics.
Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.
References
- Haschimi et coll., Cumyl-CH-MEGACLONE : métabolisme de phase I humain et caractérisation pharmacologique, J Anal Toxicol, 2021 (new tab)PMID 32514544
- Institóris et coll., Symptômes cliniques et concentrations sanguines de NPS chez des patients intoxiqués, région de Budapest (2018-2019), Clin Toxicol, 2022 (new tab)PMID 34080493
- ANSM, Décision du 22 mai 2024 portant modification de la liste des substances classées comme stupéfiants (new tab)
- ANSM, Liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026 (annexe IV) (new tab)
- OICS, Liste verte des substances psychotropes sous contrôle international, édition 2026 (new tab)
- PubChem, CUMYL-CH-MEGACLONE, CID 155884822 (new tab)
Structured data
- SMILES
- CC(C)(C1=CC=CC=C1)N2C=CC3=C(C2=O)C4=CC=CC=C4N3CC5CCCCC5
- InChIKey
- CGHCGYCTOLWAPL-UHFFFAOYSA-N
LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.